



Atty. Dkt. No. 041673-2115

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tuszynski, Mark H.

Title: METHODS FOR THERAPY OF
NEURODEGENERATIVE
DISEASE OF THE BRAIN

Appl. No.: 10/748,337

Filing Date: 12/29/2003

Examiner:

Art Unit:

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.	
<u>DIANE GARCIA</u> (Printed Name)	
<u>Diane Garcia</u> (Signature)	
4-23-04 (Date of Deposit)	

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003.

Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicant submits herewith on Forms PTO-892, PTO-1449 and PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent Application

Serial No. 09/620,174, filed July 19, 2000, now United States Patent No. 6,683,058, issued Jan. 27, 2004 and parent Application Serial No. 09/060,543, filed April 15, 1998, now United States Patent No. 6,451,306, issued Sept. 17, 2002.. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of all forms be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 2-22-04

By *Stacy L. Taylor*

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6720
Facsimile: (858) 792-6773

Stacy L. Taylor
Attorney for Applicant
Registration No. 34,842

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		APR 26 2004 Applicant: Tuszynski, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	A1	01/21/92	5,082,670	Gage et al.			
	A2	06/25/96	5,529,774	Barba et al.			
	A3	07/22/97	5,650,148	Gage et al.			
	A4	11/04/97	5,683,695	Shen et al.			
	A5	05/26/98	5,756,312	Weiner et al.			
	A6	06/09/98	5,762,926	Gage et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	A7*	06/28/90	WO 90/06757	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	A8*	Armelin et al., "Pituitary extracts and steroid hormones in the control of 3T3 cell growth" <u>Proc. Natl. Acad. Sci.</u> (1973) <u>70</u> :2702-6.
	A9*	Banerji et al., "Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences" <u>Cell</u> (1981) <u>27</u> :299-308.
	A10*	Benoist et al., "In vivo sequence requirements of the SV40 early promoter region" <u>Nature</u> (1981) <u>290</u> :304-10.
	A11*	Blesch et al., "Ex vivo gene therapy for Alzheimer's disease and spinal cord injury" <u>Clinical Neuroscience</u> (1996) <u>3</u> :268-274.
	A12*	Borsani et al., "cDNA sequence of human beta-NGF" <u>Nucleic Acids Res.</u> (1990) <u>18</u> :4020.
	A13*	Breathnach et al., "Organization and expression of eucaryotic split genes coding for proteins" <u>Ann. Rev. Biochem.</u> (1981) <u>50</u> :349-83.
	A14*	Chen et al., "Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA" <u>BioTechniques</u> (1988) <u>6</u> :632-8.
	A15*	Chen et al., "High-efficiency transformation of mammalian cells by plasmid DNA" <u>Mol. Cell. Biol.</u> (1987) <u>7</u> :2745-52.
	A16*	Chua et al., "Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts" <u>Connect. Tissue Res.</u> (1990) <u>25</u> :161-170.
	A17*	Conner et al., "Distribution of NGF delivered into the rat CNS by either grafted NGF-secreting fibroblasts, intraparenchymal (IP) injections, or IP-infusions" <u>Society for Neuroscience</u> (1997) <u>23</u> :53 Abstract 29.5.

.1

DATE CONSIDERED:

EXAMINER:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		Applicant: Tuszynski, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	A18*	Corden et al., "Promoter sequences of eukaryotic protein-coding genes." <u>Science</u> (1980) <u>209</u> :1406-14.
	A19*	DePamphilis et al., "Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals" <u>BioTechniques</u> (1988) <u>6</u> :662-80.
	A20*	de Wet et al., "The mRNAs for the pro-alpha 1(I) and pro-alpha 2(I) chains of type I procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady state ratios of the two mRNAs" <u>J. Biol. Chem.</u> (1983) <u>258</u> :14385-9.
	A21*	Elias et al., "Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma" <u>Ann. N.Y. Acad. Sci.</u> (1990) <u>580</u> :233-244.
	A22*	Felgner et al., "Cationic liposome mediated transfection" <u>Proc. West. Pharmacol. Soc.</u> (1989) <u>32</u> :115-21.
	A23*	Felgner et al., "Cationic liposome mediated transfection" <u>Focus.</u> (1989) <u>11</u> :21-25.
	A24*	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :7413-7.
	A25*	Fraley et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids" <u>Trends Biochem. Sci.</u> (1981) <u>6</u> :77-80.
	A26*	Fromm et al., "Deletion mapping of DNA regions required for SV40 early region promoter function in vivo" <u>J. Mol. Appl. Genet.</u> (1982) <u>1</u> :457-81.
	A27*	Gruss et al., "Simian virus 40 tandem repeated sequences as an element of the early promoter" <u>Proc. Natl. Acad. Sci.</u> (1981) <u>78</u> :943-7.
	A28*	Hefti et al., "Nerve growth factor and Alzheimer's disease" <u>Ann. Neurol.</u> (1986) <u>20</u> :275-81.
	A29*	Higgins et al., "NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease" <u>Exp. Neurol.</u> (1989) <u>106</u> :222-36.
	A30*	Horellou et al., "Adenovirus-mediated gene transfer to the central nervous system for Parkinson's Disease" <u>Experimental Neurobiology</u> (1997) <u>144</u> :131-8.
	A31*	Jolly et al., "Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene" <u>Nucleic Acids Res.</u> (1983) <u>11</u> :1855-1872.
	A32*	Kobayashi et al., "Morphometric study on the CH\$ of the nucleus basalis of Meynert in Alzheimer's disease" <u>Mol. Chem. Neuropathol.</u> (1991) <u>15</u> :193-206.
	A33*	Kordower et al., "The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor" <u>Proc. Natl. Acad. Sci.</u> (1994) <u>91</u> :10898-10902.
	A34*	Lehericy et al., "Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease" <u>J. Comp. Neurol.</u> (1993) <u>330</u> :15-31.
	A35*	Levivier et al., "Intrastratal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease" <u>The Jo. Of Neuroscience</u> (1995) <u>15</u> :7810-20.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

APR 26 2004

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		Applicant: Tuszynski, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	A36*	Mannino et al., "Liposome mediated gene transfer" <u>Biotechniques</u> (1988) <u>6</u> :682-90.
	A37*	Maxam et al., "Sequencing end-labeled DNA with base-specific chemical cleavages" <u>Methods in Enzymology</u> (1980) <u>65</u> :499-560.
	A38*	McCutchan et al., "Enhancement of the infectivity of simian virus 40 deoxy ribonucleic acid with diethylaminoethyl-dextran" <u>J. Natl. Cancer Inst.</u> (1968) <u>41</u> :351-7.
	A39*	Messing et al., "A system for shotgun DNA sequencing" <u>Nucleic Acids Res.</u> (1981) <u>9</u> :309-21.
	A40*	Mesulam et al., "Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey." <u>J. Comp. Neurol.</u> (1983) <u>214</u> :170-197.
	A41*	Moreau et al., "The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants" <u>Nucleic Acids Res.</u> (1981) <u>9</u> :6047-6068.
	A42*	Mufson et al., "Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain" <u>Exp. Neurol.</u> (1989) <u>105</u> :221-32.
	A43*	Mufson et al., "Nerve growth factor receptor expressing human basal forebrain neurons: pathologic alterations in Alzheimer's and Parkinson's disease" <u>Prog. Clin. Biol. Res.</u> (1989) <u>317</u> :401-14.
	A44*	Palmer et al., "Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes" <u>Proc. Natl. Acad. Sci.</u> (1991) <u>88</u> :1330-4.
	A45*	Potter et al., "Electroporation in biology: methods, applications, and instrumentation" <u>Anal. Biochem.</u> (1988) <u>174</u> :361-73.
	A46*	Prockop et al., "Heritable diseases of collagen" <u>N. Eng. J. Med.</u> (1984) <u>311</u> :376-86.
	A47*	Raymon et al., "Application of ex vivo gene therapy in the treatment of Parkinson's disease" <u>Experimental Neurobiology</u> (1997) <u>144</u> :82-91.
	A48*	Rossi et al., "Identification of a cell-specific transcriptional enhancer in the first intron of the mouse alpha 2 (type I) collagen gene" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :5590-4.
	A49*	Schmidt et al., "Regulation of a collagen promoter by the product of viral mos oncogene" <u>Nature</u> (1985) <u>314</u> :286-9.
	A50*	Seliger et al., "Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription" <u>J. Virology</u> (1988) <u>62</u> :619-21.
	A51*	Seliger et al., "Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level" <u>J. Immunol.</u> (1988) <u>141</u> :2138-44.
	A52*	Shvaloff et al., "Lines of therapeutic research in Alzheimer's disease" <u>Psychopharmacology Bulletin</u> (1996) <u>32</u> :343-52..
	A53*	Smith et al., "Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy" <u>Proc. Natl. Acad. Sci.</u> (1999) <u>96</u> :10893-8.
	A54*	Smith et al., "Characterization of collagen synthesized by normal and chemically transformed rat liver epithelial cell lines" <u>Biochem.</u> (1980) <u>19</u> :1820-5.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		APR 26 2006 PMS/TRADEMARKS JC34	
		Applicant: Tuszyński, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*


Examiner Initials	Ref. No.	Title
	A55	Toneguzzo et al., "Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells" <u>Molec. Cell. Biol.</u> (1986) <u>6</u> :703-6.
	A56	Tuszyński et al., "Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration" <u>Gene Therapy</u> (1996) <u>3</u> :305-14.
	A57	Tuszyński et al., "Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain" <u>Ann. Neurol.</u> (1991) <u>30</u> :625-36.
	A58	Tuszyński et al., "Somatic gene therapy for nervous system disease" <u>Ciba Foundation Symposium 196, Growth factors as drugs for neurological and sensory disorders</u> (1996) <u>196</u> :85-97.
	A59	Tuszyński et al., "The chronically injured spinal cord exhibits responsiveness to NGF delivered locally by gene therapy" <u>Society for Neuroscience</u> (1995) <u>21</u> :1562 Abstract 613.3.
	A60	Ullrich et al., "Human beta-nerve growth factor gene sequence highly homologous to that of a mouse" <u>Nature</u> (1983) <u>303</u> :821-5.
	A61	Wolff et al., "Expression of retrovirally transduced genes in primary cultures of rat hepatocytes" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :3344-8.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

2004


Notice of References Cited

APR 26 2004

 Application No.
09/060,543

Applicant(s)

Tuszynski et al.

Examiner

Shin-Lin Chen

Group Art Unit

1633

Page 1 of 1

U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A	5,650,148	7-22-97	Gage et al.	424	93.2
B					
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N	X WO 90/06757	6-28-90	PCT	Gage et al.	—	—
O						
P						
Q			:			
R						
S						
T						

NON-PATENT DOCUMENTS

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U	Yang et al., Journal of Neurotrauma, Vol. 14(5), p. 281-297. X	5-97
V		
W		
X		

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 041673-2043	SERIAL NO. 09/620,174
		INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT Tuszynski, Mark H.	
				FILING DATE 07/19/2000	GROUP ART UNIT 1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A1 *	Kojima, et al., "Adenovirus-Mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain," <i>Biochemical and Biophysical Research Communications</i> , 238:569-573 (1997)
A2 *	Roberts, et al., "Effects of NGF-Secreting Genetically Modified Cell Grafts on Cholinergic Neuronal Morphology and Gocnition in Aged Primates," <i>Soc. For Neuroscience Abstracts</i> , 21(2):613.8 (1995)
A3 *	Yang, et al., "Gene Therapy for Central Nervous System Injury: The Use of Cationic Liposomes: An Invited Review," <i>Journal of Neurotrauma</i> , 14(5):281-297 (1997)
A4 *	Zlokovic, et al., "Cellular and Molecular Neurosurgery: Pathways From Concept to Reality – Part II: Vector Systems and Delivery Methodologies for Gene Therapy of The Central Nervous System," <i>Neurosurgery</i> , 40(4):805-813 (1997)

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>APR 26 2004</i>		ATTY. DOCKET NO. 041673-2043	SERIAL NO. 09/620,174		
				APPLICANT Tuszynski, Mark H.			
(Use several sheets if necessary)				FILING DATE 07/19/2000	GROUP ART UNIT 1633		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A1*	Tuszynski, et al., "Targeted Intraparenchymal Delivery of Human NGF by Gene Transfer to the Primate Basal Forebrain for 3 Months Does Not Accelerate β -Amyloid Plaque Disposition," <i>Experimental Neurology</i> , Article No. EN986956 1-10 (1998).					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							

2043

D I P E

Notice of References Cited

APR 26 2004

Application/Control No.

09/620,174

Applicant(s)/Patent Under

Reexamination

TUSZYNSKI, MARK H.

Examiner

Shin-Lin Chen

Art Unit

1632

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					


NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8: 53-69.
	V	Verma et.al.; Gene therapy- promises, problems and prospects , 1997, Nature, vol. 389: 239-242.
	W	Eck et.al.;Gene-Based Therapy, 1996, Pharmacological Basis of Therapeutics: 77-101.
	X	Gorecki; Prospects and problems of gene therapy: an update, 2001, Expert Opin. Emerging Drugs 6(2): 187-198.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

2004



Notice of References Cited		Application No. 09/060,543	Applicant(s) Tuszynski et al.	
		Examiner Shin-Lin Chen	Group Art Unit 1633	Page 1 of 1

U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
B	5,762,926	6/1998	Gage et al.	424	93.21
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
V	* Blesch et al., Clinical Neuroscience, Vol. 3, p. 268-274.	1996
V		
W		
X		